• Vera Therapeutics President and CEO Marshall Fordyce sold 46,250 Class A common shares on July 7, 2026.
• Sales were priced at weighted-average prices ranging from $40.78 to $43.59.
• Directly held stake fell to 151,994 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001859453-26-000010), on July 09, 2026, and is solely responsible for the information contained therein.